A Neoadjuvant Biochemotherapy Approach to Stage III Melanoma: Analysis of Surgical Outcomes

Immunotherapy - United Kingdom
doi 10.2217/imt.12.62
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Surgical Removal of the Index Node Marked Using Magnetic Seed Localization to Assess Response to Neoadjuvant Immunotherapy in Patients With Stage III Melanoma

British Journal of Surgery
Surgery
2019English

P1.01-10 Stage III Non-Small Cell Lung Cancer Clinical Outcomes With Surgical Resection After Definitive Neoadjuvant Chemoradiotherapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Correction To: Breast-Conserving Surgery Following Neoadjuvant Therapy-A Systematic Review on Surgical Outcomes

Breast Cancer Research and Treatment
Cancer ResearchOncology
2018English

Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II-III Across European Countries: Variations and Outcomes

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Frontiers in Oncology
Cancer ResearchOncology
2017English

Does Metastasectomy Improve Survival in Patients With Stage IV Melanoma? A Cancer Registry Analysis of Outcomes

Journal of Surgical Oncology
MedicineSurgeryOncology
2011English

Biochemotherapy of Metastatic Malignant Melanoma. Predictive Value of Tumour-Infiltrating Lymphocytes

British Journal of Cancer
Cancer ResearchOncology
2001English

Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2019English

Surgical Analysis of Lymph Node Positivity After Neoadjuvant Therapy

Mastology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy